Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 1/2 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 1Lymphoid 1

Conditions

Multiple Myeloma 1Lymphoma, Non-Hodgkin 1

Interventions

Specimen Handling 149pembrolizumab 131Cyclophosphamide 118Magnetic Resonance Spectroscopy 117Biopsy 105fludarabine 89Nivolumab 62Carboplatin 54Cisplatin 49Gemcitabine 48Radiotherapy 47venetoclax 45Paclitaxel 43Cetuximab 40fludarabine phosphate 39Ipilimumab 37Fluorouracil 36atezolizumab 33Bevacizumab 33durvalumab 31Oxaliplatin 29X-Rays 28Leucovorin 28Dexamethasone 28Radiation 27Irinotecan 27Cytarabine 26Azacitidine 26Injections 24Radiosurgery 23

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × efineptakin alfa × 90 days × Clear all
NCT07052305 2026-05-13

NT-I7 (Efineptakin Alfa), a Long-acting Human IL-7, Post-Axicabtagene Ciloleucel or Post-Lisocabtagene Maraleucel in Subjects With Relapsed/Refractory Large B-cell Lymphoma

Washington University School of Medicine

Phase 1 Recruiting
24 enrolled
Lymphoid

Lymphoma, Non-Hodgkin

NCT07200089 2026-04-07

Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel)

Washington University School of Medicine

Phase 1 Not yet recruiting
52 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡